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TO THE EDITORS:
We read with interest a recent review by Toso et al.1
about liver graft allocation for patients with hepatocel-
lular carcinoma (HCC), and we wished to comment
further on the ethical implications of transplant bene-
fit allocation models.
The allocation of liver grafts to patients with end-
stage liver disease is dominated by 2 main ethical prin-
ciples: equity and utility.2 Equity criteria include hori-
zontal equity, or equal treatment for equal need, and
vertical equity, or the prioritization of those with more
severe health conditions.3,4 Horizontal equity implies
that different subgroups of patients should have similar
priority (eg, patients with and without HCC). Vertical
equity coincides with the sickest-first urgency principle.
On the other hand, utility is associated with the general
philosophical moral theory of utilitarianism.2 Whereas
treating the sickest first prioritizes those with the worst
future prospects if left untreated, utility-based alloca-
tion aims to save the most life-years or most lives.2
Toso et al.1 described urgency-based5 and utility-
based allocation models, with the latter including the
benefit concept.6
However, the survival benefit–based deceased donor
liver allocation described by several authors in the last
10 years6-10 does not always coincide with the ethical
concept of utility; this depends on the time horizon.
Time horizon is a technical term referring to the dura-
tion of observation or follow-up in a statistical model.
This term is often buried in the methods sections of
articles or not even mentioned at all, but it turns out
that decisions about time horizon have a profound ethi-
cal implication. When transplant benefit is considered
with a long-term horizon (10 years to lifetime), it is
weighted more heavily toward posttransplant outcomes
and thus reflects a “pure utility” allocation (see Fig. 1).
In this context, transplant benefit corresponds to a utili-
tarianism measure and suffers from all the biases of
cost-effectiveness studies, such as ageism and poor
long-term predictive ability.2 Conversely, transplant
benefit with a very short time horizon of 1 to 3 years is
muchmore influenced by variables predicting nontrans-
plant survival (MELD score, tumor stage, and alterna-
tive therapies available) and reflects a “pure urgency”
measure, and it risks leading to “futile” transplants of
very sick patients with poor posttransplant survival.7
The area of the time horizon between 5 and 10 years
after LT is equally influenced by pretransplant and post-
transplant variables and thus can provide what Schau-
bel et al.8 defined as a balancing role of transplant
benefit “between urgency and utility.”
In conclusion, we wish to make readers aware that the
choice of time horizon in allocation models reflects a
tradeoff between urgency and utility. In this view, trans-
plant benefit may approximate the objective of any ideal
allocation system as it is defined by some ethicists: “To
achieve a just allocation of scarce medical interventions,
society must embrace the challenge of implementing a
coherent multiprinciple framework rather than relying
on simple principles or retreating to the status quo.”2
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Figure. 1. Transplant benefit by time horizon.
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